发布求助
文献互助 智能选刊 最新文献

European Oncology and Haematology最新文献

筛选
英文 中文
Defibrotide – A New Treatment Approach for Severe Veno-occlusive Disease 去纤维肽——治疗严重静脉闭塞疾病的新方法
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.01.11
Katrina Mountfort, M. Mohty, E. Wallhult
{"title":"Defibrotide – A New Treatment Approach for Severe Veno-occlusive Disease","authors":"Katrina Mountfort, M. Mohty, E. Wallhult","doi":"10.17925/EOH.2015.11.01.11","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.11","url":null,"abstract":"Touch MEDical MEDia 11 Abstract Severe veno-occlusive disease (VOD) is a serious and life-threatening complication of haematopoietic stem cell transplantation (HSCT), for which the standard of care has until recently been supportive care. VOD is the result of a primary injury to sinusoidal endothelial cells and severe VOD is characterised by sinusoidal narrowing and occlusion, which leads to portal hypertension, multi-organ failure (MOF) and, ultimately, death. Defibrotide regulates multiple pathways involved in the pathological processes underlying VOD and is the first drug to be approved in Europe for the treatment of severe VOD. Defibrotide is indicated for the treatment of severe hepatic VOD in HSCT therapy in adults and infants aged over 1 month. A phase III study found significant increases in complete response (CR) and survival with defibrotide compared with historical controls. These data together with earlier studies and an ongoing expanded access protocol in a large patient cohort demonstrate improved outcomes with defibrotide in severe VOD and highlight the importance of treatment with defibrotide.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"9 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84596976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Treatment Options in Mantle Cell Lymphoma 套细胞淋巴瘤的新治疗方案
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.134
M. Furtado, S. Rule
{"title":"New Treatment Options in Mantle Cell Lymphoma","authors":"M. Furtado, S. Rule","doi":"10.17925/EOH.2015.11.02.134","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.134","url":null,"abstract":"Mantle cell lymphoma is an incurable disease that generally exhibits a poor prognosis. Recent advances in targeted therapies have increased the available treatment options, in particular for patients with relapsed disease, and offer the prospect for better long-term disease control and potentially chemotherapy-free treatment. Established therapies, such as proteasome inhibition and immunomodulatory agents, are beginning to be recognised as useful in the management of mantle cell lymphoma (MCL) alongside the many emerging classes of drugs (Bruton’s tyrosine kinase [BTK] inhibitors, phosphatidylinositol-4, 5-bisphosphate 3-kinase [PI3k] inhibitors and B cell lymphoma 2 [BCL2] inhibitors) that show promise in this disease. We review the newer agents and drug combinations available for the treatment of MCL.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"104 ","pages":"134"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72429282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 间变性淋巴瘤激酶阳性非小细胞肺癌的不良事件处理
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.94
C. Rolfo, I. Gil-Bazo, S. Peters
{"title":"Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer","authors":"C. Rolfo, I. Gil-Bazo, S. Peters","doi":"10.17925/EOH.2015.11.02.94","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.94","url":null,"abstract":"Touch MEdical MEdia Abstract The development of oncogene-directed targeted therapies represents a new paradigm in the treatment of non-small cell lung cancer (NSCLC), offering improved outcomes compared with chemotherapy. Rearrangements of the anaplastic lymphoma kinase (ALK) gene are major oncogenic drivers in a subset of NSCLC patients. Since its launch in 2011, the ALK inhibitor crizotinib has become the standard of care in ALK-positive NSCLC, but resistance inevitably develops. Ceritinib and alectinib have received regulatory approval: the former in Europe, US and elsewhere in the world, the latter in Japan. ALK inhibitors target multiple pathways, and may therefore be associated with a wide range of adverse events (AEs), including gastrointestinal AEs, hepatotoxicity and, in the case of crizotinib and ceritinib, cardiac effects. While the majority of these AEs are reversible, manageable and not severe, it is important that both physician and patients are aware of toxicities to ensure prompt treatment. This article discusses the management of AEs in patients receiving currently approved ALK inhibitors, including treatment, regular monitoring, drug discontinuation or dose reduction and physician/patient education. Proactive management of AEs enhances patient quality of life and optimises the therapeutic index of these agents.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"44 1","pages":"94-99"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80666107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
How Do We Move Forward with Vaccines in Lung Cancer 我们如何在肺癌疫苗方面取得进展
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.92
A. Ottevaere, N. Brucker, J. Vansteenkiste
{"title":"How Do We Move Forward with Vaccines in Lung Cancer","authors":"A. Ottevaere, N. Brucker, J. Vansteenkiste","doi":"10.17925/EOH.2015.11.02.92","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.92","url":null,"abstract":"Touch MEdical MEdia Abstract Vaccination for non-small cell lung cancer has been studied in several large phase III trials over the past decade. They confirmed excellent tolerability, but could not demonstrate outcome benefits, despite promising earlier phase II randomised studies. MAGE-A3 as Adjuvant Non-Small Cell LunG CanceR ImmunoTherapy (MAGRIT), the largest therapeutic trial ever carried out in lung cancer, with appropriate setting, power and design, answered a long-existing question: therapeutic vaccination with current technologies does not work in lung cancer. The best strategy forward may be combination of neo-epitopes vaccines and checkpoint inhibitors.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"36 1","pages":"92"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78610995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contribution of the Prosigna® (PAM50) Gene Signature Assay as a New-generation Genomic Test for Treatment Decision-making in Early Breast Cancer Prosigna®(PAM50)基因标记检测作为新一代基因组检测在早期乳腺癌治疗决策中的贡献
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.85
N. Harbeck, R. Wuerstlein, K. Sotlar
{"title":"Contribution of the Prosigna® (PAM50) Gene Signature Assay as a New-generation Genomic Test for Treatment Decision-making in Early Breast Cancer","authors":"N. Harbeck, R. Wuerstlein, K. Sotlar","doi":"10.17925/EOH.2015.11.02.85","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.85","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"16 1","pages":"85"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86138001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Front-line Management of Multiple Myeloma – How Can We Best Assess the Depth of Response? 多发性骨髓瘤的一线治疗-我们如何最好地评估反应的深度?
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.105
M. Delforge
{"title":"Front-line Management of Multiple Myeloma – How Can We Best Assess the Depth of Response?","authors":"M. Delforge","doi":"10.17925/EOH.2015.11.02.105","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.105","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"744 1","pages":"105"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76840559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision Medicine in Europe – Forging a Common Vision 欧洲的精准医疗——打造共同愿景
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.01.32
J. Martin-Moreno
{"title":"Precision Medicine in Europe – Forging a Common Vision","authors":"J. Martin-Moreno","doi":"10.17925/EOH.2015.11.01.32","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.32","url":null,"abstract":"Touch MEdical MEdia Abstract The prospect of achieving truly personalised medicine (or precision medicine) has raised patients’ hopes and piqued researchers’ curiosity, prompting the development of new -omics fields and attracting interest from the health technology industry. However, to ensure that new advances are incorporated equitably without diverting scarce resources from essential services and underserved populations, European institutions must forge a common policy that balances investments with returns and competition with coordination.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"32 1","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82751406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Atlas-based Auto-contouring - Balancing Accuracy with Efficiency in OnQ rts ® 基于阿特拉斯的自动轮廓-平衡精度与效率在onqrts®
European Oncology and Haematology Pub Date : 2014-01-01 DOI: 10.17925/EOH.2014.10.2.98
S. Barley, C. Antoine, G. Webster, M. Tiffany, N. Nundlall, R. Simmons, A. Hartley
{"title":"Atlas-based Auto-contouring - Balancing Accuracy with Efficiency in OnQ rts ®","authors":"S. Barley, C. Antoine, G. Webster, M. Tiffany, N. Nundlall, R. Simmons, A. Hartley","doi":"10.17925/EOH.2014.10.2.98","DOIUrl":"https://doi.org/10.17925/EOH.2014.10.2.98","url":null,"abstract":"Atlas-based auto segmentation with OnQ rts ® has been shown to deliver time-savings for the delineation of organs at risk in head and neck patients being treated with intensity-modulated radiotherapy. However, as the initial time to set up atlases can be high in busy departments the optimal number of atlas cases needed for auto-contouring was investigated. Using conformity index and mean distance to conformity to compare automatically generated with gold standard clinical contours, it was found that the majority of contours were unaffected by reducing the number of atlas cases from 30 to 10. The optimum number of atlas cases, however, was considered to be 20 due to the reduction in accuracy of the mandible, larynx and brain, below this level.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"14 1","pages":"98"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74542265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Oncoplasty as the Standard of Care in Breast Cancer Surgery 肿瘤成形术作为乳腺癌手术的标准护理
European Oncology and Haematology Pub Date : 2014-01-01 DOI: 10.17925/EOH.2014.10.1.43
C. Urban, K. Anselmi, F. Kuroda, J. Schwartz
{"title":"Oncoplasty as the Standard of Care in Breast Cancer Surgery","authors":"C. Urban, K. Anselmi, F. Kuroda, J. Schwartz","doi":"10.17925/EOH.2014.10.1.43","DOIUrl":"https://doi.org/10.17925/EOH.2014.10.1.43","url":null,"abstract":"© TOUCH MEDICAL MEDIA 2014 43 Abstract Oncoplastic surgery is redefining breast cancer surgery today. Despite the lack of randomised clinical trials, current evidence suggests at least equivalent oncological outcomes, reduced re-excision rates and superior aesthetic results. This review outlines the arguments for the superiority of this new approach over the current standard of care and discusses some of the difficulties with regards to training and mentoring the next generation of surgeons.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"12 4 1","pages":"43"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78305904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Head and Neck Cancer Highlights of ESMO Congress 2014 2014年ESMO大会头颈癌亮点
European Oncology and Haematology Pub Date : 2014-01-01 DOI: 10.17925/EOH.2014.10.2.96
P. Economopoulou, Giannis Kotsantis, G. Kavourakis, A. Psyrri
{"title":"Head and Neck Cancer Highlights of ESMO Congress 2014","authors":"P. Economopoulou, Giannis Kotsantis, G. Kavourakis, A. Psyrri","doi":"10.17925/EOH.2014.10.2.96","DOIUrl":"https://doi.org/10.17925/EOH.2014.10.2.96","url":null,"abstract":"Head and neck squamous cell carcinoma (HNSCC) is a challenging cancer to treat and cure. A great proportion of patients present with advanced disease and appropriate treatment options include surgical resection with adjuvant radiotherapy (RT) or chemoradiotherapy (CRT), radical concurrent CRT or RT with monoclonal antibody cetuximab. Despite improved outcomes with CRT, overall prognosis is still unsatisfactory and treatment-related toxicity is a matter of major importance. To obtain improved outcomes and mitigate disease recurrence, current research is focused on novel molecular targeted agents, immunotherapy and discovery of predictive markers. Herein, we summarise recent advances in treatment of head and neck cancer, as presented in European Society for Medical Oncology (ESMO) Congress 2014.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"2 1","pages":"96"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87133319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信